{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:04Z","timestamp":1792895584128,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP19K17652"],"award-info":[{"award-number":["JP19K17652"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03387-x","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T17:54:07Z","timestamp":1734544447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators"],"prefix":"10.1186","volume":"24","author":[{"given":"Shunichi","family":"Nishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetomo","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3387_CR1","first-page":"1419","volume":"7","author":"JB Sunwoo","year":"2001","unstructured":"Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419\u201328.","journal-title":"Clin Cancer Res"},{"key":"3387_CR2","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.3390\/jcm10173940","volume":"10","author":"J Bila","year":"2021","unstructured":"Bila J, Katodritou E, Guenova M, Basic-Kinda S, Coriu D, Dapcevic M, et al. Bone marrow microenvironment interplay and current clinical practice in multiple myeloma: a review of the Balkan myeloma study group. J Clin Med. 2021;10:3940.","journal-title":"J Clin Med"},{"key":"3387_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2010.01544.x","volume":"101","author":"D Tamura","year":"2010","unstructured":"Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2\/M transition. Cancer Sci. 2010;101:1403\u20138.","journal-title":"Cancer Sci"},{"key":"3387_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","volume":"66","author":"AM Roccaro","year":"2006","unstructured":"Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66:184\u201391.","journal-title":"Cancer Res"},{"key":"3387_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00277-010-1022-1","volume":"90","author":"WY Shi","year":"2011","unstructured":"Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, et al. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia\/lymphoma. Ann Hematol. 2011;90:53\u20138.","journal-title":"Ann Hematol"},{"key":"3387_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cas.12335","volume":"105","author":"K Yoshizawa","year":"2014","unstructured":"Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195\u2013201.","journal-title":"Cancer Sci"},{"key":"3387_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1349-7006.2007.00638.x","volume":"99","author":"Y Ogawa","year":"2008","unstructured":"Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140\u20134.","journal-title":"Cancer Sci"},{"key":"3387_CR8","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","volume":"107","author":"S Miyakoshi","year":"2006","unstructured":"Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492\u20134.","journal-title":"Blood"},{"key":"3387_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hon.924","volume":"28","author":"X Dun","year":"2010","unstructured":"Dun X, Yuan Z, Fu W, Zhang C, Hou J. Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematol Oncol. 2010;28:49\u201352.","journal-title":"Hematol Oncol"},{"key":"3387_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1532\/IJH97.06142","volume":"84","author":"A Gotoh","year":"2006","unstructured":"Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, et al. Lung injury associated with bortezomib therapy in relapsed\/refractory multiple myeloma in Japan: a questionnaire-based report from the lung injury by bortezomib joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006;84:406\u201312.","journal-title":"Int J Hematol"},{"key":"3387_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.leukres.2006.09.015","volume":"31","author":"V Pitini","year":"2007","unstructured":"Pitini V, Arrigo C, Altavilla G, Naro C. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res. 2007;31:1027\u20138.","journal-title":"Leuk Res"},{"key":"3387_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1272\/jnms.84.148","volume":"84","author":"SS Rho","year":"2017","unstructured":"Rho SS, Ando K, Fukuhara S. Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions. J Nippon Med Sch. 2017;84:148\u201359.","journal-title":"J Nippon Med Sch"},{"key":"3387_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrm1357","volume":"5","author":"E Dejana","year":"2004","unstructured":"Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261\u201370.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3387_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00441-014-1805-0","volume":"355","author":"L Duluc","year":"2014","unstructured":"Duluc L, Wojciak-Stothard B. Rho GTPases in the regulation of pulmonary vascular barrier function. Cell Tissue Res. 2014;355:675\u201385.","journal-title":"Cell Tissue Res"},{"key":"3387_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1248\/bpb.b21-00504","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Takagi Y, Ando K, Fukuhara S. Rap1 small GTPase regulates vascular endothelial-cadherin-mediated endothelial cell-cell junctions and vascular permeability. Biol Pharm Bull. 2021;44:1371\u20139.","journal-title":"Biol Pharm Bull"},{"key":"3387_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00441-013-1792-6","volume":"355","author":"J Oldenburg","year":"2014","unstructured":"Oldenburg J, de Rooij J. Mechanical control of the endothelial barrier. Cell Tissue Res. 2014;355:545\u201355.","journal-title":"Cell Tissue Res"},{"key":"3387_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature01148","volume":"420","author":"S Etienne-Manneville","year":"2002","unstructured":"Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629\u201335.","journal-title":"Nature"},{"key":"3387_CR18","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1038\/ncomms7725","volume":"6","author":"CM Mikelis","year":"2015","unstructured":"Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, et al. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nat Commun. 2015;6:6725.","journal-title":"Nat Commun"},{"key":"3387_CR19","doi-asserted-by":"publisher","first-page":"32109","DOI":"10.1038\/srep32109","volume":"6","author":"K Kobayashi","year":"2016","unstructured":"Kobayashi K, Horikami D, Omori K, Nakamura T, Yamazaki A, Maeda S, et al. Thromboxane A2 exacerbates acute lung injury via promoting edema formation. Sci Rep. 2016;6:32109.","journal-title":"Sci Rep"},{"key":"3387_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/MCB.25.1.136-146.2005","volume":"25","author":"S Fukuhara","year":"2005","unstructured":"Fukuhara S, Sakurai A, Sano H, Yamagishi A, Somekawa S, Takakura N, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol. 2005;25:136\u201346.","journal-title":"Mol Cell Biol"},{"key":"3387_CR21","doi-asserted-by":"publisher","first-page":"100428","DOI":"10.1016\/j.xpro.2021.100428","volume":"2","author":"SS Rho","year":"2021","unstructured":"Rho SS, Oguri-Nakamura E, Ando K, Yamamoto K, Takagi Y, Fukuhara S. Protocol for analysis of integrin-mediated cell adhesion of lateral plate mesoderm cells isolated from zebrafish embryos. STAR Protoc. 2021;2:100428.","journal-title":"STAR Protoc"},{"key":"3387_CR22","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1172\/JCI75247","volume":"124","author":"DS Shi","year":"2014","unstructured":"Shi DS, Smith MC, Campbell RA, Zimmerman PW, Franks ZB, Kraemer BF, et al. Proteasome function is required for platelet production. J Clin Invest. 2014;124:3757\u201366.","journal-title":"J Clin Invest"},{"key":"3387_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1083\/jcb.201606055","volume":"217","author":"I Kova\u010devi\u0107","year":"2018","unstructured":"Kova\u010devi\u0107 I, Sakaue T, Majole\u00e9 J, Pronk C, Manon, Maekawa M, Geerts D, Fernandez-Borja M, Higashiyama S, Hordijk LP, et al. The Culin-3-Rbx 1-KCTD10 complex controls endothelial barrier function via K63 ubiquitination of RhoB. J Cell Biol. 2018;217:1015\u201332.","journal-title":"J Cell Biol"},{"key":"3387_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","volume":"76","author":"CK Min","year":"2006","unstructured":"Min CK, Lee S, Kim YJ, Eom KS, Lee JW, Min WS, et al. Cutaneous leucoclastic vasculitiss (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol. 2006;76:265\u20138.","journal-title":"Eur J Haematol"},{"key":"3387_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12185-008-0194-0","volume":"88","author":"D Maruyama","year":"2008","unstructured":"Maruyama D, Watanabe T, Heike Y, Nagase K, Takahashi N, Yamasaki S, et al. Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol. 2008;88:396\u2013402.","journal-title":"Int J Hematol"},{"key":"3387_CR26","doi-asserted-by":"publisher","first-page":"30287","DOI":"10.1074\/jbc.273.46.30287","volume":"273","author":"L Wei","year":"1998","unstructured":"Wei L, Zhou W, Croissant JD, Johansen FE, Prywes R, Balasubramanyam A, et al. RhoA signaling via serum response factor plays an obligatory role in myogenic differentiation. J Biol Chem. 1998;273:30287\u201394.","journal-title":"J Biol Chem"},{"key":"3387_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI6842","volume":"103","author":"VP Sah","year":"1999","unstructured":"Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW 2nd, Ross J Jr., et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest. 1999;103:1627\u201334.","journal-title":"J Clin Invest"},{"key":"3387_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1113\/jphysiol.2001.013117","volume":"539","author":"RH Adamson","year":"2002","unstructured":"Adamson RH, Curry FE, Adamson G, Liu B, Jiang Y, Aktories K, et al. Rho and rho kinase modulation of barrier properties: cultured endothelial cells and intact microvessels of rats and mice. J Physiol. 2002;539:295\u2013308.","journal-title":"J Physiol"},{"key":"3387_CR29","doi-asserted-by":"publisher","first-page":"e00058","DOI":"10.1002\/prp2.58","volume":"2","author":"FF Stellari","year":"2014","unstructured":"Stellari FF, Sala A, Donofrio G, Ruscitti F, Caruso P, Topini TM, et al. Azithromycin inhibits nuclear factor-\u03baB activation during lung inflammation: an in vivo imaging study. Pharmacol Res Perspect. 2014;2:e00058.","journal-title":"Pharmacol Res Perspect"},{"key":"3387_CR30","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.3892\/mmr.2017.6524","volume":"15","author":"LH Hu","year":"2017","unstructured":"Hu LH, Fan YJ, Li Q, Guan JM, Qu B, Pei FH, et al. Bortezomib protects against dextran sulfate sodium-induced ulcerative colitis in mice. Mol Med Rep. 2017;15:4093\u20139.","journal-title":"Mol Med Rep"},{"key":"3387_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1902\/jop.2016.160396","volume":"88","author":"L Jiang","year":"2017","unstructured":"Jiang L, Song J, Hu X, Zhang H, Huang E, Zhang Y, et al. The proteasome inhibitor bortezomib inhibits inflammatory response of periodontal ligament cells and ameliorates experimental periodontitis in rats. J Periodontol. 2017;88:473\u201383.","journal-title":"J Periodontol"},{"key":"3387_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00277-010-1022-1","volume":"90","author":"WY Shi","year":"2011","unstructured":"Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, Leboeuf C, Janin A, Chen SJ, Zhao WL, et al. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia\/lymphoma. Ann Hematol. 2011;90:53\u20138.","journal-title":"Ann Hematol"},{"key":"3387_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1165\/rcmb.2011-0331OC","volume":"47","author":"SY Kim","year":"2012","unstructured":"Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, Lee YS, et al. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2012;47:698\u2013708.","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03387-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03387-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03387-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T18:04:22Z","timestamp":1734545062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03387-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3387"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03387-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"617"}}